全球范围内肺癌发病率和死亡率均位居众癌之首,是威胁人类健康的一大杀手。确诊时70%以上为局部晚期和晚期,失去手术治疗机会,内科治疗或联合放疗是主要的治疗方式。近十年来以表皮生长因子受体酪氨酸激酶抑制剂吉非替尼、厄罗替尼为代表的分子靶向治疗已经成为晚期非小细胞肺癌不可或缺的治疗方法。由于其针对敏感人群疗效高、缓解快、毒性低、耐受性好等特点,在临床应用中 The incidence and mortality of lung cancer in the world are ranked first in all cancer, is a major killer of human health threats. More than 70% of the diagnosed cases are locally advanced or late, and the chance of surgical treatment is lost. Internal medicine or combined radiotherapy is the main treatment. Molecular targeted therapy, such as gefitinib and erlotinib, which are epidermal growth factor receptor tyrosine kinase inhibitors in recent ten years, has become an indispensable treatment for advanced non-small cell lung cancer. Because of its high efficacy for sensitive populations, rapid response, low toxicity, good tolerance and other characteristics in clinical applications